All News

One-third of men with high-risk prostate cancer achieved pathologic complete response (pCR) or near-complete response to 6 months of preoperative therapy with abiraterone acetate (ZYTIGA), leuprolide, and prednisone, investigators reported at the American Society of Clinical Oncology annual meeting in Chicago.

Standard laparoscopic procedures are associated with more muscular contraction and trapezius muscle fatigue than robot-assisted approaches, according to a comparison of the two approaches conducted by 11 surgeons.

External application of pulsed electromagnetic fields using an investigational device (TranStim Transdermal Neuromodulation System, EMKinetics, Inc., Mountain View, CA) produces the same stimulation of the posterior tibial nerve as traditional electrical stimulation, results from a proof-of-concept study demonstrate.

Older patients with early-stage kidney cancer had significant improvement in short-term survival after partial versus radical nephrectomy but no long-term survival benefit, data from a large retrospective study showed.

The treatment benefit of intradetrusor onabotulinumtoxinA (Botox) for urinary incontinence due to neurogenic detrusor overactivity may decline after patients have received multiple repeat injections, findings from a study by Taiwanese urologists suggest.

With the presidential election looming, we thought it would be appropriate to look at the visions for health care reform put forth by the two presidential candidates, with an eye toward what a urology practice should do today to prepare for the future.

Adoption of robotic surgery for treatment of kidney cancer has led to a modest increase in the annual volume of partial nephrectomies but a substantial cost savings for care of chronic kidney disease, an economic analysis of a 6-year period suggests.

Patients with early-stage kidney cancer fared much better with partial rather than radical nephrectomy if they were candidates for either procedure, say researchers from the University of Michigan, Ann Arbor.

Responders to the multi-targeted receptor tyrosine kinase inhibitor sunitinib (Sutent) have significantly longer progression-free survival and overall survival than non-responders, according to an analysis of 1,059 patients who participated in six clinical trials of sunitinib as first- or second-line therapy of metastatic renal cell carcinoma.